Predictive factors of response to liraglutide in patients with type 2 diabetes mellitus and metabolic syndrome.

ABSTRACT:

Background

Although liraglutide has established advantages in treating patients with type 2 diabetes mellitus (T2DM) and metabolic syndrome (MS), there are still some patients with lower responsiveness to liraglutide. The objective of the study was to identify the predictors of response to liraglutide in patients with T2DM and MS.

Methods

This retrospective cohort study included patients diagnosed with T2DM and MS who received liraglutide treatment as a part of their diabetes management for a minimum of six months. The participants were stratified into two groups: responders (HbA1c reduction≥1.0% and weight loss≥3%) and non-responders. The discrepancies in baseline data between the two groups were analyzed, containing comedications, test parameters, and basic profiles. The a

SUBMITTER: Song J 

PROVIDER: S-EPMC11486649 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature